Published in CPT Pharmacometrics Syst Pharmacol on September 26, 2012
CPT: Pharmacometrics and Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol (2012) 1.65
Exposure-response modeling of clinical end points using latent variable indirect response models. CPT Pharmacometrics Syst Pharmacol (2014) 0.97
A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback. J Math Biol (2013) 0.84
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol (2015) 0.82
Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development. AAPS J (2013) 0.78
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs (2016) 0.75
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
Biologic basis for interleukin-1 in disease. Blood (1996) 16.04
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med (1990) 7.49
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am (2001) 3.58
Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol (1998) 2.77
The C-reactive protein. J Emerg Med (1999) 2.58
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today (2006) 2.21
Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics (2000) 2.14
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res (2005) 1.96
Mechanisms of interleukin-1beta release. Immunobiology (2009) 1.93
IL-1: discoveries, controversies and future directions. Eur J Immunol (2010) 1.73
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60
Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther (2001) 1.38
Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol (2010) 1.19
Canakinumab. MAbs (2010) 1.16
The many worlds of reducing interleukin-1. Arthritis Rheum (2005) 1.10
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn (2007) 1.05
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord (2011) 1.03
A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther (2009) 1.02
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem (2010) 0.97
The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm (2007) 0.92
Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci (2000) 0.90
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet (2012) 0.90
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs (2011) 0.90
A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn (2010) 0.88
Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol (2007) 0.85
Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother (2009) 0.84
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics (2010) 0.81
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol (1999) 2.07
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol (1998) 1.80
Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA (2001) 1.71
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol (2000) 1.69
Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend (1996) 1.54
Transcytosis and paracellular movements of horseradish peroxidase across liver parenchymal tissue from blood to bile. Effects of alpha-naphthylisothiocyanate and colchicine. Biochem J (1985) 1.36
Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther (2007) 1.25
The effects of colchicine on secretion into bile of bile salts, phospholipids, cholesterol and plasma membrane enzymes: bile salts are secreted unaccompanied by phospholipids and cholesterol. Biochem J (1984) 1.22
Biliary protein output by isolated perfused rat livers. Effects of bile salts. Biochem J (1983) 1.20
Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile. Biochem J (1984) 1.13
Children are not goldfish--mark/recapture techniques and their application to injury data. Inj Prev (2000) 1.11
Subtypes of adult antisocial behavior among drug abusers. J Nerv Ment Dis (1995) 1.04
Membrane fluidity and bile salt damage. Biochim Biophys Acta (1981) 1.01
Control of biliary phospholipid secretion. Effect of continuous and discontinuous infusion of taurocholate on biliary phospholipid secretion. Biochem J (1986) 0.98
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther (2012) 0.98
Self-report stability for substance use over 10 years: data from the St. Louis Epidemiologic Catchment Study. Drug Alcohol Depend (1995) 0.97
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol (1999) 0.97
Membrane lipid composition and susceptibility to bile salt damage. Biochim Biophys Acta (1980) 0.96
Network-based approaches in drug discovery and early development. Clin Pharmacol Ther (2013) 0.94
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy (2014) 0.93
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Effect of taurochenodeoxycholate or tauroursodeoxycholate upon biliary output of phospholipids and plasma-membrane enzymes, and the extent of cell damage, in isolated perfused rat livers. Biochem J (1983) 0.92
Analysis of the relative contributions of the proximal and distal epiphyseal plates to the growth in length of the tibia in the New Zealand white rabbit. Growth (1972) 0.92
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol (2006) 0.90
Nature of taurodehydrocholic acid uptake in rat hepatocytes. Am J Physiol (1988) 0.89
Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. Xenobiotica (2010) 0.88
Methods of data smoothing for instantaneous centre of rotation measurements. Med Biol Eng Comput (1984) 0.87
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol (1999) 0.85
Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening. J Urol (1999) 0.85
Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol (1999) 0.84
Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes. Biochim Biophys Acta (1982) 0.84
Function of rat hepatocyte tight junctions: studies with bile acid infusions. Am J Physiol (1991) 0.81
Effect of molecular charge on para- and transcellular access of horseradish peroxidase into rat bile. Hepatology (1989) 0.80
Knee analyser: an objective method of evaluating mediolateral stability in the knee. Med Biol Eng Comput (1977) 0.78
Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Clin Pharmacol Ther (2008) 0.78
Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. MAbs (2015) 0.75
Evaluation of serum inhibin A as a surveillance marker after conservative management of tubal pregnancy. Hum Reprod (1998) 0.75
Different influence of incongruent follicular development on in vitro fertilization-embryo transfer and gamete intrafallopian transfer pregnancy rates. Fertil Steril (1998) 0.75
Semi-flexible sockets for amputation below the knee. Arch Phys Med Rehabil (1975) 0.75
Urethral pressure profile in female stress incontinence. J Urol (1978) 0.75
The pedynograph: a clinical tool for force measurement and gait analysis in lower extremity amputees. Arch Phys Med Rehabil (1979) 0.75
Breakdown of hepatic tight junctions during reoxygenation injury. Transplantation (1992) 0.75
One parameter model for error in instantaneous centre of rotation measurements. J Biomech (1984) 0.75
A catheter withdrawing apparatus for clinical urethral pressure profile studies. J Urol (1976) 0.75
Pyruvate kinase activity in the lymphocytes of malnourished, anergic patients. J Surg Res (1980) 0.75
Physical disability: the role of the physical scientist in the health service. A report of the Institute of Physical Sciences in Medicine. Clin Phys Physiol Meas (1988) 0.75
A force-indicating spreader. A tool for teaching the Harrington technique. Spine (Phila Pa 1976) (1982) 0.75
Re: The use of gemeprost pessaries to arrest postpartum haemorrhage. Aust N Z J Obstet Gynaecol (1997) 0.75
Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer. J Urol (1999) 0.75
An inexpensive chart-reading instrument. Med Biol Eng (1973) 0.75